Avicanna Announces Repayment of Debentures
30 août 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Announces Closing of Non-Brokered Private Placement
28 août 2024 18h15 HE
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
27 août 2024 07h30 HE
|
Avicanna Inc.
USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topicalcannabinoid composition and methods for treating musculoskeletal inflammation and pain ...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
15 août 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
Avicanna Reports Q2 2024
14 août 2024 17h45 HE
|
Avicanna Inc.
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE)...
Avicanna Announces Changes of Auditors
02 août 2024 17h30 HE
|
Avicanna Inc.
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
11 juil. 2024 07h30 HE
|
Avicanna Inc.
This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc....
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
10 juil. 2024 17h30 HE
|
Avicanna Inc.
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna General Meeting
19 juin 2024 17h30 HE
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
19 juin 2024 07h30 HE
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...